| Myostatin is a key mediator between energy metabolism and endurance capacity of skeletal muscle E Mouisel, K Relizani, L Mille-Hamard, R Denis, C Hourdé, O Agbulut, ... American Journal of Physiology-Regulatory, Integrative and Comparative …, 2014 | 88 | 2014 |
| Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy K Relizani, E Mouisel, B Giannesini, C Hourdé, K Patel, SM Gonzalez, ... Molecular therapy 22 (8), 1423-1433, 2014 | 87 | 2014 |
| Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model K Relizani, G Griffith, L Echevarría, F Zarrouki, P Facchinetti, C Vaillend, ... Molecular Therapy-Nucleic Acids 8, 144-157, 2017 | 65 | 2017 |
| Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system PO Buclez, GD Florencio, K Relizani, C Beley, L Garcia, R Benchaouir Molecular Therapy Methods & Clinical Development 3, 2016 | 47 | 2016 |
| Combined Effect of AAV-U7-Induced Dystrophin Exon Skipping and Soluble Activin Type IIB Receptor in mdx Mice WMH Hoogaars, E Mouisel, A Pasternack, JJ Hulmi, K Relizani, ... Human gene therapy 23 (12), 1269-1279, 2012 | 43 | 2012 |
| The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo C Kropp, K Le Corf, K Relizani, K Tambosco, C Martinez, F Chain, ... Scientific reports 11 (1), 11494, 2021 | 41 | 2021 |
| Combinatory effects of si RNA‐induced myostatin inhibition and exercise on skeletal muscle homeostasis and body composition S Mosler, K Relizani, E Mouisel, H Amthor, P Diel Physiological reports 2 (3), e00262, 2014 | 38 | 2014 |
| Characterization of a Dmd EGFP reporter mouse as a tool to investigate dystrophin expression MV Petkova, S Morales-Gonzales, K Relizani, E Gill, F Seifert, J Radke, ... Skeletal muscle 6, 1-16, 2016 | 26 | 2016 |
| Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides K Relizani, L Echevarría, F Zarrouki, C Gastaldi, C Dambrune, P Aupy, ... Nucleic Acids Research 50 (1), 17-34, 2022 | 24 | 2022 |
| Evaluating the impact of variable phosphorothioate content in tricyclo-DNA antisense oligonucleotides in a duchenne muscular dystrophy mouse model L Echevarría, P Aupy, K Relizani, T Bestetti, G Griffith, F Blandel, ... nucleic acid therapeutics 29 (3), 148-160, 2019 | 23 | 2019 |
| Aav production using baculovirus expression vector system Q Sandro, K Relizani, R Benchaouir Viral Vectors for Gene Therapy: Methods and Protocols, 91-99, 2019 | 19 | 2019 |
| Identifying and avoiding tcDNA-ASO sequence-specific toxicity for the development of DMD exon 51 skipping therapy P Aupy, L Echevarría, K Relizani, F Zarrouki, A Haeberli, M Komisarski, ... Molecular Therapy-Nucleic Acids 19, 371-383, 2020 | 16 | 2020 |
| Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn’s disease K Relizani, K Le Corf, C Kropp, R Martin-Rosique, D Kissi, G Déjean, ... Scientific Reports 12 (1), 6017, 2022 | 15 | 2022 |
| Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo N Béchir, É Pecchi, K Relizani, C Vilmen, Y Le Fur, M Bernard, H Amthor, ... American Journal of Physiology-Endocrinology and Metabolism 310 (7), E539-E549, 2016 | 14 | 2016 |
| Use of Tricyclo-DNA antisense oligonucleotides for exon skipping K Relizani, A Goyenvalle Exon Skipping and Inclusion Therapies: Methods and Protocols, 381-394, 2018 | 12 | 2018 |
| Extracellular matrix remodelling is associated with muscle force increase in overloaded mouse plantaris muscle A Stantzou, K Relizani, S Morales‐Gonzalez, C Gallen, A Grassin, A Ferry, ... Neuropathology and Applied Neurobiology 47 (2), 218-235, 2021 | 11 | 2021 |
| The use of Tricyclo-DNA oligomers for the treatment of genetic disorders P Aupy, L Echevarría, K Relizani, A Goyenvalle Biomedicines 6 (1), 2, 2017 | 11 | 2017 |
| Partial Restoration of Brain Dystrophin and Behavioral Deficits by Exon Skipping in the Muscular Dystrophy X‐Linked (mdx) Mouse F Zarrouki, K Relizani, F Bizot, T Tensorer, L Garcia, C Vaillend, ... Annals of Neurology 92 (2), 213-229, 2022 | 8 | 2022 |
| The use of antisense oligonucleotides for the treatment of duchenne muscular dystrophy K Relizani, A Goyenvalle Duchenne Muscular Dystrophy: Methods and Protocols, 171-183, 2018 | 7 | 2018 |
| European society of gene and cell therapy french society of cell and gene therapy collaborative congress 2012 october 25–29, 2012 palais des congrès de versailles, France T VandenDriessche, RA Pearson, RJ Chandler, CC Bartholomae, ... Hum. Gene Ther 23 (10), 2012 | 2 | 2012 |
